Aclaris Therapeutics

158 articles about Aclaris Therapeutics

• Aclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater China

  11/29/2022

  Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, and Pediatrix Therapeutics, Inc. (Pediatrix), a pediatrics-focused therapeutic company, today announced that the companies have entered into a license agreement.

• Aclaris Therapeutics Announces Key Leadership Transitions

  11/22/2022

  Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, announced several key leadership changes.

• Aclaris Therapeutics to Participate in Two November 2022 Healthcare Investor Conferences

  11/10/2022

  Aclaris Therapeutics, Inc. announced that the company will participate in two November healthcare investor conferences.

• Aclaris Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

  11/8/2022

  Aclaris Therapeutics, Inc. today announced its financial results for the third quarter of 2022 and provided a corporate update.

• Aclaris Therapeutics Appoints Robert Doody as Vice President, Investor Relations

  9/27/2022

  Aclaris Therapeutics, Inc. announced that it has appointed Robert A. Doody Jr. as Vice President, Investor Relations.

• Aclaris Therapeutics Announces Patent License Agreement with Lilly for Alopecia Areata

  8/25/2022

  Aclaris Therapeutics, Inc. today announced a non-exclusive patent license agreement with Eli Lilly and Company (Lilly).

• Aclaris Therapeutics to Participate in the Jefferies Healthcare Conference - June 01, 2022

  6/1/2022

  Aclaris Therapeutics, Inc. announced that Dr. Neal Walker, President and CEO of Aclaris, will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 11:30 a.m. ET in New York, New York.

• Aclaris Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

  5/16/2022

  Aclaris Therapeutics, Inc. announced that Dr. Neal Walker, President and CEO of Aclaris, will virtually present a company overview at the H.C. Wainwright Global Investment Conference, which will be available beginning on Tuesday, May 24, 2022 at 7:00 a.m. ET.

• Aclaris Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update

  5/10/2022

  Aclaris Therapeutics, Inc. announced its financial results for the first quarter of 2022 and provided a corporate update.

• Aclaris Therapeutics to Participate in the LifeSci Partners Immunology & Inflammation Symposium

  5/3/2022

  Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO, and Walter Smith, Scientific and Business Development Consultant, of Aclaris will participate in a virtual fireside chat at the LifeSci Partners Immunology & Inflammation Symposium.

• Aclaris Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

  2/24/2022

  Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year of 2021 and provided a corporate update.

• Aclaris Therapeutics to Participate in the SVB Leerink Virtual 11th Annual Global Healthcare Conference

  2/2/2022

  Aclaris Therapeutics, Inc. announced that Dr. Neal Walker, President and CEO of Aclaris, will participate in a fireside chat at the SVB Leerink Virtual 11th Annual Global Healthcare Conference on Wednesday, February 16, 2022 at 9:20 a.m. ET.

• Aclaris Therapeutics Expands Leadership Team

  2/1/2022

  Aclaris Therapeutics, Inc. today announced the appointment of James Loerop as Chief Business Officer, effective January 31, 2022.

• Aclaris Therapeutics Provides R&D Update

  1/11/2022

  Aclaris Therapeutics, Inc. provides an update on the status of certain of its clinical programs and on its research and development operations.

• Aclaris Therapeutics to Participate in the H.C. Wainwright BioConnect Virtual Conference

  12/27/2021

  Aclaris Therapeutics, Inc. today announced that Dr. Neal Walker, President and CEO of Aclaris, will participate in a fireside chat at the H.C. Wainwright BioConnect Virtual Conference, which will be available beginning on Monday, January 10, 2022 at 7:00 a.m. ET.

• Aclaris Therapeutics Announces Publication of Preclinical Research of Zunsemetinib in Pancreatic Cancer in Science Translational Medicine

  12/3/2021

  Aclaris Therapeutics, Inc. today announced the publication of preclinical research of zunsemetinib in pancreatic cancer in the peer-reviewed journal Science Translational Medicine, on December 1, 2021.

• Aclaris Therapeutics to Host Virtual R&D Day on December 7, 2021

  11/18/2021

  Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it will host a virtual R&D Day on Tuesday, December 7, 2021 from 10:00 a.m. to 12:00 p.m. ET.

• Aclaris Therapeutics to Participate in Upcoming Investor Conferences - Nov 03, 2021

  11/3/2021

  Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, announced that management will participate in the following upcoming investor conferences:

• Aclaris Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update

  11/2/2021

  Aclaris Therapeutics, Inc. today announced its financial results for the third quarter of 2021 and provided a corporate update.

• Aclaris Therapeutics to Participate in Upcoming Investor Conferences - Aug 26, 2021

  8/26/2021

  Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, announced that management will participate in the following upcoming investor conferences: